Adult Dosing & Uses
Immunization Against Measles, Mumps & Rubella
19-49 years old: 0.5 mL SC; second dose may be adminsitered 28 days apart
>50 years old: 0.5 mL SC; administer 1 dose only
Other Information
Mainly administered to children
Up-to-date vaccination schedules available at www.cdc.gov/nip/publications
Other Indications & Uses
2nd dose recommended for: Student in postsecondary eduction; recent exposure; occupational risk; previously vaccinated with killed measles vaccine; vaccinated with unknown type of measles vaccine during 1963-67; international travelers
Pediatric Dosing & Uses
Immunization Against Measles, Mumps & Rubella
>12 months old: 0.5 mL SC; administer second dose by 11th or 12th birthday
Inject SC into outer aspect of upper arm
Drug Interactions
Interaction Checker
No Results
Contraindicated
Serious - Use Alternative
Significant - Monitor Closely
Minor
Adverse Effects
Suspected adverse events after administration of any vaccine may be reported to Vaccine Adverse Events Reporting System (VAERS), 1-800-822-7967
Frequency Not Defined
Fever
Syncope
Pain at site
Headache
Rash
Lymphadenopathy
Myalgia
Stevens-Johnson syndrome
Thrombocytopenia
Optic neuritis
Encephalitis
Malaise
Irritability
Guillain-Barre synd
Subacute sclerosing panencephalitis (rare)
Contraindications & Cautions
Contraindications
Allergy to neomycin or gelatin
Pregnancy
HIV: CD4+ count <200 cells/ mcL
Other immunocompromised conditions (excl medication & radiation)
Cautions
Avoid pregnancy for 3 mth after vaccination
Pregnancy & Lactation
Pregnancy Category: C
Lactation: not known if excreted in breast milk
A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA:Information not available.
Pharmacology
Duration: Not established
These products convey active immunity via stimulation of production of endogenously produced antibodies
The onset of protection from disease is relatively slow, but duration is long lasting (years)
Pharmacogenomics
HLA-B7, HLA-B51, HLA-DRB1*13, and HLADQA1*01 is associated with a measles vaccine response
Homozygosity at HLA-B, HLA-DR, and HLA-DQA1 has been associated with a measles vaccine nonresponse
Mechanism of Action
Live, attenuated viruses stimulate active immunity
